MARKET

ASND

ASND

Ascendis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

143.74
-3.18
-2.16%
Opening 11:20 03/08 EST
OPEN
145.00
PREV CLOSE
146.91
HIGH
148.00
LOW
143.36
VOLUME
61.69K
TURNOVER
--
52 WEEK HIGH
183.98
52 WEEK LOW
92.00
MARKET CAP
7.73B
P/E (TTM)
-16.8113
1D
5D
1M
3M
1Y
5Y
Ascendis Pharma A/S Announces Full Year 2020 Financial Results and Business Update Conference Call on March 10
COPENHAGEN, Denmark, March 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that ...
GlobeNewswire · 3d ago
Proactive news headlines including BetterLife Pharma, HempFusion Wellness, Pure Gold Mining, Mirasol Resources and OTC Markets Group
- Medexus Pharmaceuticals Inc (CVE:MDP) shares climb as Canaccord Genuity upgrades rating to Buy from Hold following fiscal 3Q results click here
GlobeNewswire · 4d ago
Ascendis Pharma A/S Announces New "Outgrow GHD" Educational Resource to Support Rare Disease Day 2021
Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the launch of Outgrow GHD, a new online educational resource designed to help caregivers of c...
GlobeNewswire · 02/26 12:05
Prostaglandin E2 Receptor EP2 Subtype Market Analysis, Size, Share, Trends and Forecast 2020-2027
Comserve · 02/22 11:54
Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare Conference
COPENHAGEN, Denmark, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that t...
GlobeNewswire · 02/18 21:05
Prostaglandin E2 Receptor EP2 Subtype Market 2021 Top Manufacturers Strategy, Industry Share, Growth Factors, Development Trends and 2027 Forecast| Industry Research Biz
Feb 17, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Prostaglandin E2 Receptor EP2...
The Express Wire · 02/17 05:24
3 Companies With High Quality Balance Sheets to Consider
GuruFocus News · 02/10 15:22
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team
Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private biopharmaceutical and medical device companies.
BusinessWire · 01/26 13:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ASND. Analyze the recent business situations of Ascendis Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ASND stock price target is 188.02 with a high estimate of 211.70 and a low estimate of 163.68.
EPS
Institutional Holdings
Institutions: 259
Institutional Holdings: 65.42M
% Owned: 121.72%
Shares Outstanding: 53.75M
TypeInstitutionsShares
Increased
66
1.24M
New
43
1.21M
Decreased
53
1.62M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.16%
Pharmaceuticals & Medical Research
+1.13%
Key Executives
Chairman/Senior Vice President/General Counsel/Director
Michael Wolff Jensen
Chairman/Senior Vice President/Director
Michael Jensen
President/Chief Executive Officer/Executive Director
Jan Moeller Mikkelsen
Chief Financial Officer/Senior Vice President/IR Contact Officer
Scott Smith
Senior Vice President/Chief Administrative Officer
Lotte Soenderbjerg
Senior Vice President
Vibeke Breinholt
Senior Vice President
Flemming Jensen
Senior Vice President
Thomas Larson
Senior Vice President
Jens Okkels
Senior Vice President
Dana Pizzuti
Senior Vice President
Juha Punnonen
Senior Vice President
Kennett Sprogoee
Chief Accounting Officer/Vice President - Finance
Peter Rasmussen
Independent Director
Lisa Bright
Independent Director
Albert Cha
Independent Director
James Healy
Independent Director
Lars Holtug
Independent Director
Birgitte Volck
No Data
About ASND
ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.

Webull offers kinds of Ascendis Pharma A/S stock information, including NASDAQ:ASND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASND stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASND stock methods without spending real money on the virtual paper trading platform.